[name of file], 1 From Cardiac Safety To SAFE PCI Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director,

Slides:

Advertisements

Similar presentations

1 Danica Marinac – Dabic, M.D., Ph.D. Chief, Epidemiology Branch Office of Surveillance and Biometrics Center for Devices and Radiological Health Postmarket.

Advertisements

National Cardiovascular Research Infrastructure (NCRI) Summary Slide Set May 5, 2010.

Brief Introduction Clinical Trials Transformation Initiative (CTTI) Judith M. Kramer, MD, MS, Executive Director Associate Professor of Medicine, Duke.

Leveraging Operational Cardiovascular Registries: An ACC View Plenary Session: Novel Infrastructure for Clinical Trials & Innovation CSRC Transradial Thinktank.

Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.

FDA’s Critical Path to New Medical Product Development Opportunities from the Center for Devices and Radiological Health Larry Kessler, Sc.D., Director.

A-1 Pravastatin-Aspirin Introduction Todd Baumgartner, MD, MPH Vice President Regulatory Sciences Pharmaceutical Research Institute Bristol-Myers Squibb.

Produce Safety Rule Phase 2 Workgroup 1.

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Department of Medicine Research Retreat 2/9/13 Breakout Session #4: Enhancing Industry-sponsored Research Opportunities Marco Costa, MD, PHD Neal Meropol,

Few Patients With Functional MR Are Treated Surgically: Duke Database Results Mitchell W. Krucoff MD FACC, FAHA, FSCAI Professor of Medicine /

Kathryn Camp, M.S., R.D., CSP Consultant to the Office of Dietary Supplements National Institutes of Health Secretary’s Advisory Committee on Heritable.

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

1 The ACTION Public-Private Partnership: Background, Rationale, and Objectives Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia, and Addiction.

Complex Coronary Interventions (CCI) Course A New Learning Pathway by TERUMO ® Interventional Systems.

Innovation Through Collaboration: Why the CSS Working Groups are Important to the FDA Steve Wilson, DrPH, CAPT USPHS Director, FDA/CDER/OTS/OB/DBIII 2014.

NHII 03 Safety and Quality Group A David W. Bates, MD, MSc Brigham and Women’s Hospital, and Partners Healthcare System David W. Bates, MD, MSc Brigham.

The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.

Safe PCI for Women: View from the Pharmaceutical Industry Mark B. Effron, MD, FACC, FAHA, FCCP Medical Fellow Cardiovascular Medical Affairs Eli Lilly.

The “Centers for Education & Research on Therapeutics” (CERTs) Funding Opportunity Announcements FOAs RFA-HS and RFA-HS Technical Assistance.

Industry Prospective Robin Bostic, Thoratec VP Health Policy and Health Economics INTERMACS Industry Sub-Committee Representative Our Future.

The CERTs Model for Stakeholder Engagement Public-Private Partnership Hugh H. Tilson, MD, DrPH Chair, CERTs National Steering Committee September 10, 2008.

Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Critical Path Initiative Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD/CDRH.

Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD President, The Critical Path Institute.

Cardiovascular Consortium Effective Health Care Program Art Sedrakyan, MD, PhD Center for Outcomes & Evidence, AHRQ.

Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.

Post-Procedure Debriefing: Opportunities to Improve Cath Lab Communication and Patient Care Michael A. Kutcher, MD, FSCAI Henry S. Jennings, III, MD, FSCAI.

REGISTRY APPROACHES in DEVICE SURVEILLANCE Fred H. Edwards, MD Director, STS Research Center Emeritus Professor, University of Florida.

Steven Cantor Life Medical Technologies, Inc. Steven A. Cantor and His Efforts in Cardiovascular Disease Treatment.EECP Treatment for Patients with Angina.

Transradial Best Practices for Radial Access

Novel Trial Design Focus - Left Main and “All Comers” DES Studies: All-Comers Studies. Interventional View Jeffrey J. Popma, MD Director, Innovations in.

Evolving Importance of Post-Approval Studies

Regulatory Perspectives on Real World Evidence (RWE)

Clinical Review Process for New Drug Development and Application

ANALGESIC, ANESTHETIC, AND ADDICTION CLINICAL TRIAL TRANSLATIONS, INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTTION) Public-Private Partnership WITH.

Will we ever see a dedicated bifurcated DES in clinical practice?

CRT ACHIEVEMENT AWARD 20 YEARS

Impact of Radial Access on Bleeding

Mitchell W. Krucoff, MD, FACC

FDA Perspective on Cardiovascular Device Development

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

Japan-USA Synergies: Academic View

Laura Mauri, MD, MSc Brigham and Women’s Hospital

Obligatory Drug-Device Interactions-Why The Critical Path

Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.

Transradial Approach for the Female Sex

Why Radial Access Should be the Default for Women undergoing PCI?

The TREAT Study: Can Devices Lower Bleeding Rates?

Disclosures Advisory Board: Abbott Vascular Boston Medical.

Regulatory Synergies in Device Innovation

On-Site Surgical Back-up is ‘Critically’ Important for PCI!

SYNTAX at 2 Years: This Interventionalist’s Perspective

CDRH 2010 Strategic Priorities

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Transradial Intervention as Access of Choice in STEMI

Lessons Learned: Past Present and Future Japan-USA Regulatory Interactions Erica Takai, PhD US Food and Drug Administration

MACE Trial Rationale, Study Design, and Current Status

MDEpiNetMDEpiNet MDEpiNet MDEpiNetMDEpiNetMDEpinet

Lessons Learned Through HBD: The Regulator’s View - US FDA

Innovation: A Priority for FDA

CSS Clinical Trial Launched: January 2018

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

RAPID and VISION September 10, 2018 VISION Think Tank Meeting

Clinical Event Classification: Strategies and Practices

Tobey Clark, Director*, Burlington USA

Presentation transcript:

[name of file], 1 From Cardiac Safety To SAFE PCI Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Co-Director, CSRC Duke Clinical Research Institute Cardiac Safety Research Consortium

Cardiac Safety Research Consortium (CSRC): A Critical Path Public Private Partnership FDA-Duke Memo Of Understanding safety.org -safety.org  Pre-competitive focus  Multi-stakeholder perspectives  Regulatory/public health landscape  “Thinktank-incubator” processes: 1.Barrier identification 2.Prioritization 3.Partnered solutions 4. Proof-of-concept projects

[name of file], 3 Trans-Radial Education, Assessment &Training The TREAT Initiative Obligatory Device-Drug Safety Interaction: Impact of device technique on drug safety *CSRC SOC Approved Research Project *

The TREAT Initiative Launch

TransRadial Education, Assessment & Therapy: June 2010 Regulatory n FDA: l CDER l CDRH l OC OWH Regulatory n FDA: l CDER l CDRH l OC OWH Academia n Duke n Harvard n Cleveland Clinic n Columbia n Emory n Johns Hopkins n Mayo Clinic n Wash Hrt Ctr Academia n Duke n Harvard n Cleveland Clinic n Columbia n Emory n Johns Hopkins n Mayo Clinic n Wash Hrt Ctr Industry n Abbott n Medtronic n Terumo n Cordis/J&J n The MEDCO n Eli Lilly (Daichi) n Sanofi/BMS Industry n Abbott n Medtronic n Terumo n Cordis/J&J n The MEDCO n Eli Lilly (Daichi) n Sanofi/BMS Societies n ACC n SCAI n ESC n SOLACI Societies n ACC n SCAI n ESC n SOLACI Federal n NIH n AHRQ Federal n NIH n AHRQ

 Fruit of pre-competitive PPP (cardiac safety FDA-Duke critical path program)  First & only USA PCI study of women  Unique public health concern  POC for unique research infrastructure

CSRC Consensus White Papers

NIH-NCRI: Linking to the ACC-NCDR for SAFE RCT Efficiency in a “River” of E-Information  Index hosp:  Pt descriptors  Medications  Procedural details  Adverse events  65% workload reduction

Building on SAFE PCI for Women: SAFE STEMI for Seniors n Public health: Radial vs. Femoral Intervention l Women l Seniors n Regulatory: l OWH l IDE extension n RCT operations: linked registry efficiencies l Short term F/U: NCRI-NCDR Cath PCI Index hosp: descriptors, meds, procedure, SAEs Index hosp: descriptors, meds, procedure, SAEs l Long term F/U: CMS Claims Data (Seniors) 1 year death, MI, stroke 1 year death, MI, stroke n Collaborating Partners: l ACC, CSRC, DCRI, FDA-OWH, NIH, Medical Device & Drug Industry l ACC, CMS, CSRC, DCRI, FDA-CDRH, NHLBI, NIA, Medical Device & Drug Industry

 Dr. Danica Marinac-Dabic (FDA)  Dr. Arthur Sedrakyan (Cornell)  Dr. Sharon-Lise Normand (Harvard)  Dr. Mitchell Krucoff (Duke)

Overview of Today’s Agenda n Plenary: Partnered Approaches to Improving Data Quality & Efficiency n SAFE PCI for Women n Lunch n SAFE STEMI for Seniors l Scientific issues l Operational issues

[name of file], 12 From Cardiac Safety To SAFE PCI Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Co-Director, CSRC Duke Clinical Research Institute Cardiac Safety Research Consortium